Aprea Therapeutics, Inc. (APRE) stock
APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45+0.05 (+11.52%)
Close on Nov 17, 2026Market cap $5.71MP/E –Yield –
Aprea Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Aprea Therapeutics's total assets was $42.29M at Jun 30, 2026. For fiscal 2025 it was $15.93M, down 33.6% from the year before. The highest annual figure on record is $133.61M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.93M | -33.6% |
| FY2024 | Dec 31, 2024 | $23.98M | +5.9% |
| FY2023 | Dec 31, 2023 | $22.65M | -24.9% |
| FY2022 | Dec 31, 2022 | $30.16M | -46.9% |
| FY2021 | Dec 31, 2021 | $56.82M | -38.8% |
| FY2020 | Dec 31, 2020 | $92.81M | -30.5% |
| FY2019 | Dec 31, 2019 | $133.61M | +102.4% |
| FY2018 | Dec 31, 2018 | $66.02M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $42.29M | +144.3% |
| Q1 FY2026 | Mar 31, 2026 | $47.61M | +135.4% |
| Q4 FY2025 | Dec 31, 2025 | $15.93M | -33.6% |
| Q3 FY2025 | Sep 30, 2025 | $14.32M | -46.7% |
| Q2 FY2025 | Jun 30, 2025 | $17.31M | -42.2% |
| Q1 FY2025 | Mar 31, 2025 | $20.22M | -39.1% |
| Q4 FY2024 | Dec 31, 2024 | $23.98M | +5.9% |
| Q3 FY2024 | Sep 30, 2024 | $26.89M | +4.4% |
| Q2 FY2024 | Jun 30, 2024 | $29.96M | +4.5% |
| Q1 FY2024 | Mar 31, 2024 | $33.20M | +3.7% |
| Q4 FY2023 | Dec 31, 2023 | $22.65M | -24.9% |
| Q3 FY2023 | Sep 30, 2023 | $25.77M | -23.4% |
| Q2 FY2023 | Jun 30, 2023 | $28.68M | -29.5% |
| Q1 FY2023 | Mar 31, 2023 | $32.02M | -36.4% |
| Q4 FY2022 | Dec 31, 2022 | $30.16M | -46.9% |
| Q3 FY2022 | Sep 30, 2022 | $33.62M | -46.2% |
| Q2 FY2022 | Jun 30, 2022 | $40.68M | -43.1% |
| Q1 FY2022 | Mar 31, 2022 | $50.34M | -37.4% |
| Q4 FY2021 | Dec 31, 2021 | $56.82M | -38.8% |
| Q3 FY2021 | Sep 30, 2021 | $62.48M | -39.2% |
| Q2 FY2021 | Jun 30, 2021 | $71.55M | -37.7% |
| Q1 FY2021 | Mar 31, 2021 | $80.39M | -35.7% |
| Q4 FY2020 | Dec 31, 2020 | $92.81M | -30.5% |
| Q3 FY2020 | Sep 30, 2020 | $102.83M | +79.4% |
| Q2 FY2020 | Jun 30, 2020 | $114.82M | +73.9% |
| Q1 FY2020 | Mar 31, 2020 | $125.13M | – |
| Q4 FY2019 | Dec 31, 2019 | $133.61M | – |
| Q3 FY2019 | Sep 30, 2019 | $57.34M | – |
| Q4 FY2018 | Dec 31, 2018 | $66.02M | – |
See a number that looks wrong?